AI-HEART Lab Clinical Tools
2025 AHA/ACC Hypertension Guideline Calculator
Guideline-informed decision-support across 9 integrated modules. Enter patient data, classify blood pressure, and generate AI-powered clinical notes.
How It Works HIPAA Compliant
Paste EHR Note
Copy and paste a prior or active clinical note from your EHR below
AI Extracts Data
AI identifies BP readings, medications, labs, and comorbidities automatically
Review & Confirm
Verify extracted values and adjust if needed
Generate AI Note
One-click structured “# Hypertension” note with guideline references
Pathophysiology of Hypertension
RAAS overactivation, sympathetic nervous system dysregulation, endothelial dysfunction, arterial stiffness, renal sodium retention, and vascular remodeling. How each drug class targets these mechanisms.
Explore mechanisms →Landmark Trials That Shaped the 2025 Guideline
- SPRINT: Intensive SBP target <120 reduced CV events 25% and mortality 27% vs standard <140
- STEP: Intensive treatment in elderly Chinese adults reduced CV events 26% (SBP 110–130 vs 130–150)
- ESPRIT: Confirmed benefit of intensive BP lowering (<120 vs <140) in Chinese patients
- BPROAD: Intensive BP lowering in T2DM patients with high CVD risk reduced MACE 21%
- CHAP: Treating chronic HTN in pregnancy to <140/90 reduced adverse pregnancy outcomes without harm
Stay Current on Hypertension Evidence
— landmark trials and significant new findings, with AI-contextualized summaries
0 of 9 modules completed
IMPORTANT: This software is clinical decision support (CDS) intended for use by licensed healthcare professionals under Section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act. It is not intended as a medical device. All recommendations are derived from the 2026 ACC/AHA Guideline on the Management of Dyslipidemia and must be independently verified by the treating clinician before any clinical action. AI-generated content (including extracted data and clinical notes) is produced by large language models and may contain errors, omissions, or hallucinations — clinician review is mandatory. Patient data entered into the calculator is processed entirely in the browser; AI features process data server-side under a signed HIPAA Business Associate Agreement with no data retention. AI-HEART Lab, its affiliates, and contributors assume no liability for clinical decisions made using this tool. By using this tool, you acknowledge these limitations and accept full responsibility for clinical decisions.
Calculator computation is 100% client-side. Opt-in AI features process data server-side under a signed HIPAA BAA with no data retention.
About This Tool
This calculator implements the 2025 AHA/ACC Guideline for the Diagnosis and Management of Hypertension in Adults. Every clinical threshold — BP classification boundaries, treatment initiation criteria, drug selection hierarchies, BP goal targets, and monitoring intervals — is mapped directly to the corresponding guideline figure, table, or recommendation with Class of Recommendation (COR) and Level of Evidence (LOE) cited.
The tool integrates the PREVENT 10-year CVD risk score from the lipid guideline calculator to inform treatment initiation decisions for Stage 1 hypertension, reflecting the 2025 guideline's emphasis on risk-stratified care. Nine core modules cover BP classification, treatment initiation, medication selection, BP goals, comorbidity-specific management, resistant HTN, special populations, lifestyle modifications, and monitoring & follow-up.
Calculator computation occurs entirely in your browser. Opt-in AI features (data extraction, note generation, email delivery) process clinical data server-side under a signed HIPAA Business Associate Agreement — data is held in memory only and never persisted or logged.
What Changed in the 2025 Hypertension Guideline
The 2025 AHA/ACC Guideline for the Diagnosis and Management of Hypertension represents a major update from the 2017 guideline. Published in September 2025, it introduces risk-stratified treatment initiation, renewed emphasis on combination therapy, and updated terminology for severe hypertension.
New BP Classification Thresholds
Stage 1 HTN starts at 130/80 mmHg. Elevated BP remains 120–129/<80 mmHg. Treatment thresholds are now risk-stratified via the PREVENT risk score, with Stage 1 HTN at <10% 10-year risk receiving lifestyle modifications only. This replaces the previous approach of treating all Stage 1 HTN with medications if risk-enhancing factors were present.
Single-Pill Combination Therapy
The 2025 guideline places new emphasis on early combination therapy with single-pill combinations (SPC) rather than sequential monotherapy titration. For Stage 2 HTN (≥140/90) or high-risk Stage 1 HTN, initial 2-drug SPC is preferred. Preferred pairs include ACEi/ARB + DHP-CCB (especially for diabetes, per the ACCOMPLISH trial), ACEi/ARB + thiazide, or DHP-CCB + thiazide. Triple SPCs (olmesartan/amlodipine/HCTZ) are recognized for patients requiring three agents.
Updated Severe HTN Terminology
The term “hypertensive urgency” has been replaced by “severe HTN without target organ damage.” Hypertensive emergency remains defined as BP ≥180/120 mmHg with acute target organ damage. The guideline provides detailed IV agent selection algorithms by emergency type — aortic dissection, acute stroke, ACS, and eclampsia each have specific first-line IV agents and MAP reduction targets.
Universal BP Goal <130/80 mmHg
The guideline sets a universal target of <130/80 mmHg for most treated adults. For high-risk ASCVD patients, SBP <120 mmHg may be considered when tolerated, supported by SPRINT (25% CV event reduction), STEP, and ESPRIT trial data. The previous exception for uncomplicated elderly patients has been removed — intensive targets are now recommended across age groups when tolerated.
Resistant HTN & New Fourth-Line Agents
Resistant HTN criteria have been clarified: uncontrolled on ≥3 agents (including a diuretic) at optimal doses, or controlled requiring ≥4 agents. Out-of-office BP confirmation (ABPM/HBPM) is mandated before escalation. Spironolactone remains the preferred 4th agent (PATHWAY-2 trial). For patients where MRA is contraindicated, aprocitentan (PRECISION trial) is recognized as a new option.
Why Use This Calculator
9 Integrated Clinical Modules
Each module maps directly to the guideline's clinical decision algorithms: BP classification, treatment initiation with PREVENT risk integration, medication selection with comorbidity-aware drug hierarchies, BP goals by patient profile, comorbidity-specific management (CKD, HF, diabetes, CAD, stroke, AF, PAD), resistant HTN evaluation, special populations (pregnancy, elderly, severe HTN), lifestyle modification BP reduction estimates, and monitoring & follow-up schedules. Patient data flows between modules — a BP classification in Module 1 automatically informs treatment recommendations in subsequent modules.
EHR-Ready Clinical Notes
Every module generates a structured “# Hypertension” clinical note summarizing BP classification, risk stratification, medication recommendations, and guideline references with COR/LOE citations. One click copies the note to your clipboard for direct paste into your EHR — no reformatting required.
Privacy and Data Handling
Calculator computation runs entirely in your browser with no server transmission. There are no user accounts, no cookies storing clinical data, and no analytics tracking patient inputs. Opt-in AI features (data extraction, note generation, email delivery) process clinical data server-side under a signed HIPAA Business Associate Agreement — data is held in memory only and never persisted or logged.
Built by a Practicing Cardiologist
This calculator was developed by Dr. Rahul Chaudhary, a practicing cardiologist (FACP, FACC) and physician-scientist with 150+ peer-reviewed publications, 18 international guideline citations, and training at Johns Hopkins University and UPMC, former faculty at Mayo Clinic Rochester. Every clinical threshold is mapped to a specific guideline figure or table with source documentation.
Frequently Asked Questions
What changed in the 2025 AHA/ACC Hypertension Guideline?
The 2025 guideline redefines Stage 1 HTN at 130/80 mmHg, integrates PREVENT 10-year CVD risk into treatment initiation decisions, emphasizes early combination therapy with single-pill combinations (SPC) over sequential monotherapy, replaces “hypertensive urgency” with “severe HTN without target organ damage,” and sets a universal BP goal of <130/80 mmHg for most patients.
What are the new blood pressure classification thresholds?
Normal BP is <120/80 mmHg. Elevated BP is 120–129/<80 mmHg. Stage 1 HTN is 130–139/80–89 mmHg. Stage 2 HTN is ≥140/≥90 mmHg. Hypertensive crisis remains ≥180/≥120 mmHg with or without acute target organ damage.
When should antihypertensive medication be started?
Medication is recommended for all Stage 2 HTN (≥140/90). For Stage 1 HTN (130–139/80–89), medication is recommended if the patient has clinical ASCVD, diabetes, CKD, or a 10-year PREVENT CVD risk ≥10%. Stage 1 HTN with <10% risk receives lifestyle modifications only.
What is the recommended blood pressure goal?
The universal target is <130/80 mmHg for most adults on pharmacotherapy. For high-risk ASCVD patients, <120 mmHg systolic may be considered when tolerated, based on SPRINT trial evidence showing 25% reduction in CV events and 27% reduction in mortality.
What is the preferred first-line combination therapy?
The guideline recommends 2-drug single-pill combinations (SPC) for Stage 2 HTN or high-risk Stage 1 HTN. Preferred pairs include ACEi/ARB + DHP-CCB (preferred for diabetes per ACCOMPLISH trial), ACEi/ARB + thiazide, or DHP-CCB + thiazide. ACEi and ARB should never be combined.
How is resistant hypertension defined and treated?
Resistant HTN is BP above goal despite ≥3 antihypertensives (including a diuretic) at optimal doses, or BP controlled requiring ≥4 agents. After confirming adherence and excluding pseudo-resistance with ABPM/HBPM, spironolactone 25 mg daily is the preferred 4th agent (PATHWAY-2 trial). Alternatives include amiloride, beta-blockers, or alpha-blockers when MRA is contraindicated.
Does this calculator store or transmit patient data?
Calculator computation occurs entirely in your browser with no server transmission. Opt-in AI features (data extraction, AI-generated notes, email delivery) process clinical data server-side under a signed HIPAA Business Associate Agreement — data is held in memory only during the request and is never persisted, cached, or logged.
What special populations does this calculator cover?
The calculator includes modules for pregnancy (chronic and gestational HTN with CHAP trial evidence), elderly patients (ages 65–79 and ≥80 with STEP trial data), severe HTN without target organ damage, hypertensive emergencies with IV agent selection, perioperative HTN, secondary HTN evaluation, and resistant HTN with adherence assessment.
Reference
Whelton PK, Carey RM, Mancia G, et al. 2025 AHA/ACC Guideline for the Diagnosis and Management of Hypertension in Adults. Hypertension. 2025. doi:10.1161/HYP.0000000000000116
Developed by AI-HEART Lab
Built by Dr. Rahul Chaudhary, a physician-scientist with 150+ publications and 18 international guideline citations, trained at Johns Hopkins University and UPMC, former faculty at Mayo Clinic Rochester.